Author:
Lappi-Blanco Elisa,Mäkinen Johanna M.,Lehtonen Siri,Karvonen Henna,Sormunen Raija,Laitakari Kirsi,Johnson Shirley,Mäkitaro Riitta,Bloigu Risto,Kaarteenaho Riitta
Funder
Foundation of the Finnish Anti-Tuberculosis Association
Jalmari and Rauha Ahokas Foundation
National Graduate School of Clinical Investigation
Northern Finland Cancer Foundation
State Subsidy of the Oulu University Hospital
Otto A. Malm Foundation
Väinö and Laina Kivi Foundation
Publisher
Springer Science and Business Media LLC
Reference44 articles.
1. Bafna S, Kaur S, Batra SK. Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene. 2010;29:2893–904.
2. Kohno N, Akiyama M, Kyoizumi S, Hakoda M, Kobuke K, Yamakido M. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol. 1988;18:203–16.
3. Hilkens J, Buijs F, Hilgers J, et al. Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer. 1984;34:197–206.
4. Jarrard JA, Linnoila RI, Lee H, Steinberg SM, Witschi H, Szabo E. MUC1 is a novel marker for the type II pneumocyte lineage during lung carcinogenesis. Cancer Res. 1998;58:5582–9.
5. Ohgami A, Tsuda T, Osaki T, et al. MUC1 mucin mRNA expression in stage I lung adenocarcinoma and its association with early recurrence. Ann Thorac Surg. 1999;67:810–4.
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献